Navigation Links
Notre Dame researcher's paper examines the biology of tumor-derived microvesicles
Date:6/21/2012

A new paper by Crislyn D'Souza-Schorey, professor of biological sciences at the University of Notre Dame, discusses the biology of tumor-derived microvesicles and their clinical application as circulating biomarkers. Microvesicles are membrane-bound sacs released by tumor cells and can be detected in the body fluids of cancer patients.

The World Health Organization (WHO) estimates that the incidence of cancer will reach approximately 9 million deaths in 2015. The rising prevalence of the disease is a major factor that drives the growth of the oncology biomarkers market. Biomarkers can be defined as any biological, chemical or physical parameter that can be utilized as an indicator of physiological or disease status. Thus, biomarkers are useful in cancer screening and detection, drug design and also to boost the effectiveness of cancer care by allowing physicians to tailor therapies for individual patientsan approach known as personalized medicine.

The new paper discusses the potential of microvesicles to present a combination of disease and tissue-specific markers that would constitute a unique, specific and identifiable biosignature for individual cancers.

"As such, it would make their sampling over time a preferred method to monitor changes to the tumor in response to treatment, especially for tissues such as the ovary or pancreas, where repeated biopsies of these organs is impractical," D'Souza-Schorey said.

Profiling of microvesicles could form the basis of personalized, targeted cancer therapies, especially as more reliable and rapid profiling technologies become available.

"For example, certain markers like HER2/neu, in addition to being elevated in breast cancer, is also increased in a relatively smaller subset of other cancers such as ovarian cancer," D'Souza-Schorey said. "This latter group of patients would benefit from existing treatment strategies that target the HER2 receptor."

The approach
'/>"/>

Contact: Crislyn-D'Souza-Schorey
cdsouzas@nd.edu
574-631-3735
University of Notre Dame
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Nanoparticles engineered at Notre Dame promise to improve blood cancer treatment
2. Moffitt researchers: Darwins principles say cancer will always evolve to resist treatment
3. Controversial vaccine trial should never have been run in India, researchers say
4. Researchers create the first GPS for the blind
5. Researchers find gold nanoparticles capable of unzipping DNA
6. Cedars-Sinai researchers, with stem cells, advance understanding of spinal muscular atrophy
7. Researchers reveal crucial immune fighter role of the STING protein
8. MDS researchers join forces to advance patient treatments and outcomes
9. Stanford researchers discover the African cichlids noisy courtship ritual
10. Researchers determine pathway for origin of most common form of brain and spinal cord tumor
11. UCI researchers create mosquitoes incapable of transmitting malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 24 (HealthDay News) -- New research suggests a ... people with insomnia. Every additional hour someone ... percent drop in the likelihood of moderate or ... the University of Pennsylvania. "We were ... sleep duration and suicide risk," study author, Linden ...
(Date:5/24/2013)... commonly used to treat glaucoma may cause droopy eyelids ... according to a new study. The drugs, known ... eye pressure, have already been shown to cause blurred ... said, suggesting that the new findings could lead to ... conservative when prescribing these drugs, the researchers added, particularly ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Area homeowners dreaming ... of new hot tubs to choose from at factory-direct pricing ... . The sales event takes place at Emerald Pool ... 2013. , Jacuzzi, the industry's leading hot tub brand, ... across the country. The event will feature popular hot tub ...
(Date:5/24/2013)... mutations central to the development of infantile myofibromatosis (IM)a ... and soft tissuemay provide new therapeutic targets, according to ... Sinai. The findings, published in the American Journal ... options for this debilitating disease, for which the only ... tumors. , IM is an inheritied disorder that develops ...
(Date:5/24/2013)... (HealthDay News) -- People with high levels of cadmium ... of liver disease than those with lower levels, a ... in urine is evidence of long-term exposure to the ... tobacco smoke, the Johns Hopkins researchers explained. They ... directly causes liver disease but instead suggest an association ...
Breaking Medicine News(10 mins):Health News:Sleep Duration Linked to Suicidal Thoughts in People With Insomnia 2Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Truckload of Jacuzzi® Hot Tubs Rolls into Bend, Oregon on May 24, 2013 for Sales Event 2Health News:Researchers identify first drug targets in childhood genetic tumor disorder 2Health News:High Cadmium Levels May Raise Risk for Dying From Liver Disease: Study 2
... Jan. 13 Genomma Lab Internacional,S.A.B. de C.V. (BMV: ... the main preliminary indicators obtained at the close of ... slightly lower results than the,original growth expectations. However, product ... line with original projections. , ...
... welcomes Los Angeles Mayor Antonio Villaraigosa, Cal State ... representatives and other dignitaries for the construction dedication ... 13 Today, Grifols SA (Grifols), a global ... Los Angeles Mayor Antonio Villaraigosa., Cal State LA ...
... WASHINGTON, Jan. 13 Speaker Nancy Pelosi released ... bipartisan legislation to expand the State Children,s Health ... Similar bipartisan legislation was vetoed twice by President ... bill, click here http://www.speaker.gov/newsroom/legislation?id=0270: "Today, the House ...
... The following was released today by the Office of the ... , On Wednesday, ... Health Insurance Program (SCHIP) Reauthorization bill. This bipartisan bill ... 11 million children -- preserving coverage for the 7 ...
... SRA International, Inc. (NYSE: SRX ), ... and solutions to government organizations and commercial clients, will ... release after close of market on Thursday, Feb. 5, ... call beginning at 5 p.m. EST.Interested parties may listen ...
... helped with pain, fatigue and depression, study shows ... may help people living with the chronic pain ... quality of life, new research shows. , The ... Saarbrucken in Germany, found that fibromyalgia patients had ...
Cached Medicine News:Health News:Grifols Celebrates Initial Construction of New IVIG Facility with Los Angeles Officials and Dignitaries 2Health News:H.R. 2, Bipartisan Children's Health Bill, Will Provide Coverage to 11 Million Children 2Health News:H.R. 2, Bipartisan Children's Health Bill, Will Provide Coverage to 11 Million Children 3Health News:H.R. 2, Bipartisan Children's Health Bill, Will Provide Coverage to 11 Million Children 4Health News:SRA Schedules Second Quarter Fiscal Year 2009 Earnings Release and Conference Call 2
(Date:5/23/2013)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... Chief Executive Officer of Neurocrine Biosciences, will be presenting at ... Conference in Boston.   The live presentation takes ... / 8:20 a.m. Pacific Time.  The presentation will be webcast ... http://www.neurocrine.com . If you are unable to ...
(Date:5/23/2013)... 23, 2013 Nephros, Inc. (OTC Bulletin Board: ... company that develops and sells high performance liquid purification ... offering.  In addition, the concurrent temporary reduction in exercise ... May 17, 2013. Nephros estimates that it ... rights offering.   A portion of the proceeds will be ...
(Date:5/23/2013)... May 23, 2013  A recently published clinical study ... Houston, Texas , demonstrates that 3D mammography (breast ... detection. The study, "Implementation of Breast ... was led by Stephen L. Rose ... the American Journal of Roentgenology (AJR). The ...
Breaking Medicine Technology:Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3
... POH, AIM: PSG, OTCQX: PPGNY) today announced that, ... Phase 1 transdermal,oxycodone clinical trial aimed at providing ... Phosphagenics has submitted all necessary documents for ... at CMAX - an independent clinical research,organization located ...
... First internal candidate to enter Phase 2 clinical ... PCOP ), an innovator in the discovery ... the initiation of a Phase 2a,clinical study of ... a dual-acting angiotensin and endothelin receptor antagonist,(DARA) that ...
Cached Medicine Technology:Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial 2Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 2Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 3Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 4Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 5
... Aegis CheckPoint is an automated, ... logging and alert system for refrigerator, ... replace chart recorders, data loggers and ... installs on an existing PC and ...
... as three tests confirmed Sterillium Rub's extremely ... to FDA (Time Kill study and Tentative ... Products) and one European test - with ... relevant international efficacy specifications. Sterillium Rub with ...
Chlorhexidine Gluconate, exceptionally persistent and broad spectrum antimicrobial properties have led to its recognition as the most effective agent available for surgical scrubbing, hand washing, p...
Amino+Derm moisturizers and soaps are specifically engineered to aid in the prevention of skin irritations and to help maintain healthy, intact skin....
Medicine Products: